Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 161

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 161
---
31, 2022, consisting of payments of the promissory note, including a prepayment of $900,000. The following table summarizes the Company’s cash flows for the nine months ended September 30, 2024, and 2023:

| ​                                                   | ​ 
 ​ 
 ​ | For the Nine Months Ended September 30, |       2024 | ​ |   |       2023 | ​ |
|:----------------------------------------------------|:--|:----------------------------------------|-----------:|:--|:--|-----------:|:--|
| Net cash used in operating activities               | ​ | $                                       | -3,568,456 | ​ | $ | -5,366,635 |   |
| Net cash used in investing activities               | ​ | ​                                       |    -19,138 | ​ | ​ |          — | ​ |
| Net cash provided by (used in) financing activities | ​ | ​                                       | -5,854,696 | ​ | ​ | 13,910,320 | ​ |
| Net increase (decrease) in cash                     | ​ | $                                       | -9,442,290 | ​ | $ |  8,543,685 | ​ |

Cash Flows from Operating Activities Net cash used in operating activities for the nine months ended September 30, 2024, was $3,568,456, which primarily reflected the Company’s net loss of $5,045,350, in addition to noncash adjustments to reconcile net loss to net cash used in operating activities of

95

$824,807 consisting primarily of depreciation and amortization and change in the fair value of derivative liability, the Company also had changes in operating assets and liabilities of $2,301,701 largely driven by accrued product returns provision and API.

Net cash used in operating activities for the nine months ended September 30, 2023, was $5,366,635 which primarily reflected our net loss of $8,481,338, in addition to noncash adjustments to reconcile net loss to net cash used in operating activities of $4,231,207 consisting primarily of depreciation and amortization, costs associated with the Private Placement, and changes in operating assets and liabilities of $1,116,504.

Cash Flows from Investing Activities

Net cash used in investing activities was $19,138 for the nine months ended September 30, 2024, consisting of $19,138 for the purchase of office equipment for use in the